Published in PLoS One on December 29, 2010
Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity (1998) 17.27
Histocompatibility antigen-activated cytotoxic T lymphocytes. II. Estimates of the frequency and specificity of precursors. J Exp Med (1977) 3.30
Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. J Clin Invest (1997) 3.13
Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol (2001) 2.93
A new look at T cells. J Exp Med (1998) 2.51
CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest (1997) 2.39
Organ transplantation--how much of the promise has been realized? Nat Med (2005) 2.26
The frequency of antigen-sensitive cells in tissue transplantation. A commentary on clonal selection. J Exp Med (1969) 2.15
Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. J Immunol (1999) 2.13
RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood (2003) 1.62
A sensitive method for detecting proliferation of rare autoantigen-specific human T cells. J Immunol Methods (2003) 1.59
Early cellular events in a systemic graft-vs.-host reaction. I. The migration of responding and nonresponding donor lymphocytes. J Exp Med (1975) 1.57
T-cell allorecognition and transplant rejection: a summary and update. Am J Transplant (2003) 1.56
Donor-specific T-cell reactivity identifies kidney transplant patients in whom immunosuppressive therapy can be safely reduced. Transplantation (2000) 1.55
A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. J Immunol Methods (1999) 1.46
Loss of direct and maintenance of indirect alloresponses in renal allograft recipients: implications for the pathogenesis of chronic allograft nephropathy. J Immunol (2001) 1.43
Rapid decreases in donor-specific cytotoxic T lymphocyte precursor frequencies and graft outcome after liver and lung transplantation. Transplantation (2001) 1.42
Quantitative analysis of lymphocyte differentiation and proliferation in vitro using carboxyfluorescein diacetate succinimidyl ester. Immunol Cell Biol (1999) 1.39
Pretransplant donor-specific helper T cell reactivity as a tool for tailoring the individual need for immunosuppression. Transplantation (2001) 1.39
Evolution of the enzyme-linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool. Am J Transplant (2002) 1.38
Contribution of naïve and memory T-cell populations to the human alloimmune response. Am J Transplant (2009) 1.34
Histocompatibility antigen-activated cytotoxic T lymphocytes. I. Estimates of the absolute frequency of killer cells generated in vitro. J Exp Med (1977) 1.33
High-resolution characterization of cytokine-producing alloreactivity in naive and allograft-primed mice. Transplantation (1998) 1.27
Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12 months in renal-transplant recipients. Transplantation (2004) 1.25
CD4+CD25+ regulatory T cells do not significantly contribute to direct pathway hyporesponsiveness in stable renal transplant patients. J Am Soc Nephrol (2003) 1.23
DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends Immunol (2004) 1.22
Are primary alloresponses truly primary? Int Immunol (1990) 1.21
CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood (2005) 1.17
Preferential priming of alloreactive T cells with indirect reactivity. Am J Transplant (2009) 1.15
B cells can prime naive CD4+ T cells in vivo in the absence of other professional antigen-presenting cells in a CD154-CD40-dependent manner. Eur J Immunol (2005) 1.13
T-cell allorecognition: a case of mistaken identity or déjà vu? Trends Immunol (2008) 1.10
A renewable source of donor cells for repetitive monitoring of T- and B-cell alloreactivity. Am J Transplant (2005) 1.10
Use of cell-tracking dyes to determine proliferation precursor frequencies of antigen-specific T cells. Methods Mol Biol (2004) 1.05
Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J Am Soc Nephrol (2008) 1.04
Trafficking of host- and donor-derived dendritic cells in rat cardiac transplantation: allosensitization in the spleen and hepatic nodes. Transplantation (2001) 1.01
The role of the allograft in the induction of donor-specific T cell hyporesponsiveness. Transplantation (2001) 0.99
A novel pathway of antigen presentation by dendritic and endothelial cells: Implications for allorecognition and infectious diseases. Transplantation (2006) 0.96
A novel assay for assessment of HIV-specific cytotoxicity by multiparameter flow cytometry. Cytometry A (2005) 0.92
CD40 activation: potential for specific immunotherapy in B-CLL. Ann Oncol (2004) 0.91
Systemic transmigration of allosensitizing donor dendritic cells to host secondary lymphoid organs after rat liver transplantation. Hepatology (2008) 0.89
Modified ELISPOT technique--highly significant inverse correlation of post-Tx donor-reactive IFNgamma-producing cell frequencies with 6 and 12 months graft function in kidney transplant recipients. Transpl Immunol (2006) 0.89
CD4+CD25bright+ regulatory T cells can mediate donor nonreactivity in long-term immunosuppressed kidney allograft patients. Am J Transplant (2006) 0.89
A direct method for the calculation of alloreactive CD4+ T cell precursor frequency. Transplantation (1999) 0.88
In vivo roles of donor and host dendritic cells in allogeneic immune response: cluster formation with host proliferating T cells. J Leukoc Biol (2001) 0.88
Multiparameter precursor analysis of T-cell responses to antigen. J Immunol Methods (2003) 0.87
Clonotype analysis of human alloreactive T cells: a novel approach to studying peripheral tolerance in a transplant recipient. J Immunol (2000) 0.87
Detection of alloreactive T cells by flow cytometry: a new test compared with limiting dilution assay. Transplantation (2002) 0.86
Decreased donor-specific cytotoxic T cell precursor frequencies one year after clinical lung transplantation do not reflect transplantation tolerance: a comparison of lung transplant recipients with or without bronchiolitis obliterans syndrome. Transplantation (2000) 0.85
Failure of mature dendritic cells of the host to migrate from the blood into cardiac or skin allografts. Transplantation (1990) 0.81
Tracking alloreactive cell division in vivo. Transplantation (1999) 0.80
Activation of alloreactive T cells by allogeneic nonprofessional antigen-presenting cells and interleukin-12 from bystander autologous professional antigen-presenting cells. Transplantation (2000) 0.79
Generation and characterization of a novel anti-rat CD40L antibody with inhibitory activities in vitro and in vivo. J Immunol Methods (2008) 0.78
The granzyme B and interferon-gamma enzyme-linked immunospot assay as alternatives for cytotoxic T-lymphocyte precursor frequency after renal transplantation. Transplantation (2005) 0.78
Migration of allosensitizing donor myeloid dendritic cells into recipients after liver transplantation. Liver Transpl (2010) 0.78
B cells as a cellular adjuvant: induction or control of T-cell immunity--or both? Expert Rev Vaccines (2007) 0.77
Reversibility with interleukin-2 suggests that T cell anergy contributes to donor-specific hyporesponsiveness in renal transplant patients. J Am Soc Nephrol (2002) 0.76
Management in patients with liver cirrhosis and an umbilical hernia. Surgery (2007) 4.09
Clearance of influenza virus from the lung depends on migratory langerin+CD11b- but not plasmacytoid dendritic cells. J Exp Med (2008) 3.97
Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology (2005) 3.10
Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proc Natl Acad Sci U S A (2013) 2.99
Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP). Anesth Analg (2002) 2.41
Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest (2004) 2.40
Cytokine gene polymorphisms and acute liver graft rejection: a meta-analysis. Liver Transpl (2005) 2.21
Pylorus preserving pancreaticoduodenectomy versus standard Whipple procedure: a prospective, randomized, multicenter analysis of 170 patients with pancreatic and periampullary tumors. Ann Surg (2004) 2.16
Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation. Liver Transpl (2012) 1.98
Selective decontamination of the digestive tract to prevent postoperative infection: a randomized placebo-controlled trial in liver transplant patients. Crit Care Med (2002) 1.98
A J-shaped subcostal incision reduces the incidence of abdominal wall complications in liver transplantation. Liver Transpl (2008) 1.96
The need for a prophylactic gastrojejunostomy for unresectable periampullary cancer: a prospective randomized multicenter trial with special focus on assessment of quality of life. Ann Surg (2003) 1.84
Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg (2004) 1.79
Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. Br J Haematol (2004) 1.67
Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med (2003) 1.59
Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Liver Transpl (2010) 1.59
Fatigue is a major problem after liver transplantation. Liver Transpl (2006) 1.56
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
Physical fitness, fatigue, and quality of life after liver transplantation. Eur J Appl Physiol (2007) 1.52
Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl (2002) 1.51
Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4+FOXP3+ regulatory T cells. Transplantation (2009) 1.50
Correction of head movement on PET studies: comparison of methods. J Nucl Med (2006) 1.50
DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection. Eur J Immunol (2007) 1.50
Intrahepatic detection of FOXP3 gene expression after liver transplantation using minimally invasive aspiration biopsy. Transplantation (2007) 1.49
Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology (2004) 1.46
Cancer inflammation and inflammatory biomarkers: can neutrophil, lymphocyte, and platelet counts represent the complexity of the immune system? Transpl Int (2014) 1.45
Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain (2008) 1.45
High-dose intravenous immunoglobulin does not reduce the numbers of circulating CD14(+)CD16(++) monocytes in patients with inflammatory disorders. Clin Immunol (2012) 1.39
Allergen-induced accumulation of airway dendritic cells is supported by an increase in CD31(hi)Ly-6C(neg) bone marrow precursors in a mouse model of asthma. Blood (2002) 1.36
Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol (2008) 1.35
Predicting the unpredictable: a new prediction model for operating room times using individual characteristics and the surgeon's estimate. Anesthesiology (2010) 1.35
Study of direct and indirect parametric estimation methods of linear models in dynamic positron emission tomography. Med Phys (2008) 1.34
Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology (2012) 1.33
Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice. Clin Immunol (2008) 1.29
Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother (2007) 1.26
A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res (2010) 1.25
Simultaneous targeting of HCV replication and viral binding with a single lentiviral vector containing multiple RNA interference expression cassettes. Mol Ther (2006) 1.24
Attenuation correction synthesis for hybrid PET-MR scanners: application to brain studies. IEEE Trans Med Imaging (2014) 1.22
Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi). Gut (2011) 1.21
Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci U S A (2004) 1.21
Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther (2008) 1.19
Closing emergency operating rooms improves efficiency. J Med Syst (2007) 1.18
Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res (2012) 1.18
Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Res (2008) 1.18
Functional Differences between Human NKp44(-) and NKp44(+) RORC(+) Innate Lymphoid Cells. Front Immunol (2012) 1.17
Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol (2004) 1.16
CD83 expression on dendritic cells and T cells: correlation with effective immune responses. Eur J Immunol (2007) 1.15
Experimental models for hepatitis C viral infection. Hepatology (2009) 1.15
The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Res (2009) 1.14
Attenuated expression of A20 markedly increases the efficacy of double-stranded RNA-activated dendritic cells as an anti-cancer vaccine. J Immunol (2009) 1.12
Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res (2012) 1.11
Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother (2011) 1.11
Engineering dendritic cells to enhance cancer immunotherapy. Mol Ther (2011) 1.10
Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology (2006) 1.10
A survey of approaches for direct parametric image reconstruction in emission tomography. Med Phys (2008) 1.08
Improving operating room efficiency by applying bin-packing and portfolio techniques to surgical case scheduling. Anesth Analg (2007) 1.08
Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). Transplantation (2010) 1.07
Adjuvant 5-FU-based chemoradiotherapy for patients undergoing R-1/R-2 resections for pancreatic cancer. Dig Surg (2005) 1.05
Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients. Mol Ther (2012) 1.05
A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein. J Immunol (2003) 1.04
Quiescent period respiratory gating for PET/CT. Med Phys (2010) 1.03
Activation of immature monocyte-derived dendritic cells after transduction with high doses of lentiviral vectors. Hum Gene Ther (2007) 1.02
Impact of immunosuppressive drugs on CD4+CD25+FOXP3+ regulatory T cells: does in vitro evidence translate to the clinical setting? Transplantation (2008) 1.02
Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry study. Transpl Int (2011) 1.02
Epidemiology and management of chronic hepatitis E infection in solid organ transplantation: a comprehensive literature review. Rev Med Virol (2013) 1.01
Low circulating regulatory T-cell levels after acute rejection in liver transplantation. Liver Transpl (2006) 1.01
The effect of rabbit anti-thymocyte globulin induction therapy on regulatory T cells in kidney transplant patients. Nephrol Dial Transplant (2009) 1.01
Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res (2009) 1.00
Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo. Hepatology (2012) 1.00
Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J Immunol (2008) 1.00
Are cytokine gene polymorphisms related to in vitro cytokine production profiles? Liver Transpl (2003) 0.99
MicroRNAs in bile vesicles: finding a trade-off for biomarker discovery. Hepatology (2015) 0.99
Defining early human NK cell developmental stages in primary and secondary lymphoid tissues. PLoS One (2012) 0.98
Induction of macrophage scavenger receptor MARCO in nonalcoholic steatohepatitis indicates possible involvement of endotoxin in its pathogenic process. Int J Exp Pathol (2004) 0.98
Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial. Ann Surg (2008) 0.98
Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols. Mol Ther (2004) 0.98
Barrett's oesophagus is characterized by a predominantly humoral inflammatory response. J Pathol (2005) 0.97